Implementation of decentralized clinical trials in Korea from a resource-based perspective
Translational and Clinical Pharmacology · 2026 · 34 (2) · 100
DOI: 10.12793/tcp.2026.34.e9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational and Clinical Pharmacology, 2026. Verfasst von Ki Young Huh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080,…. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute.
Abstract (Originalsprache)
Clinical trials in South Korea are heavily concentrated in Seoul, limiting patient access in other regions.We conducted a cross-sectional ecological study of 17 Korean administrative divisions to assess regional infrastructure readiness for decentralized clinical trial (DCT) implementation, using data from the Health Insurance Review and Assessment Service (2024), the National Health Insurance Service (2024), and the Ministry of Food and Drug Safety (2024 to 2025).Provincial densities for four resource domains (specialists, nurses, beds, and medical equipment) were calculated per 100,000 patients and normalized to Seoul (= 1.00).Area-specific composite indices for four therapeutic areas were computed as the capped geometric mean of specialist and equipment densities, and an overall infrastructure index as the capped geometric mean of all four domain densities.Trial density was derived from 1,924 approved trials yielding 7,760 trial-center pairs (99% mapping rate).Among the 16 non-Seoul provinces, bed density was the most dispersed (coefficient of variation [CV] = 0.39, range 0.58 to 2.91), whereas specialist density was the most Seoul-concentrated of the four domains: no non-Seoul province reached 80% of Seoul's level (CV = 0.23, range 0.42 to 0.79).The four therapeutic-area composite indices showed comparable dispersion (CV 0.15 to 0.23; composite infrastructure CV 0.16; Pearson r = 0.72).Gwangju exhibited the largest gap between infrastructure capacity (index 0.94) and trial activity (density ratio 0.18).Clinical trial activity in Korea is disproportionately low relative to infrastructure, and regionspecific DCT strategies matched to local resource profiles can provide a practical framework for balanced trial participation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
- Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, Korea.
- Division of Clinical Pharmacology, Chonnam National University Hospital, Gwangju 61469, Korea.
- Department of Cardiology, Chonnam National University Medical School, Hwasun 58128, Korea.
- Department of Cardiology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju 61469, Korea.
ORCID-Profile: Ki Young Huh, Gaeun Kang, Kye Hun Kim
Förderung
- Korea Health Industry Development Institute
Zitieren
APA
Huh, K. Y., Kang, G., & Kim, K. H. (2026). Implementation of decentralized clinical trials in Korea from a resource-based perspective. Translational and Clinical Pharmacology, 34(2), 100. https://doi.org/10.12793/tcp.2026.34.e9
Vancouver
Huh KY, Kang G, Kim KH. Implementation of decentralized clinical trials in Korea from a resource-based perspective. Translational and Clinical Pharmacology. 2026;34(2):100. doi:10.12793/tcp.2026.34.e9
BibTeX
@article{Huh2026,
author = {Huh, Ki Young and Kang, Gaeun and Kim, Kye Hun},
title = {Implementation of decentralized clinical trials in Korea from a resource-based perspective},
journal = {Translational and Clinical Pharmacology},
year = {2026},
volume = {34},
number = {2},
pages = {100},
doi = {10.12793/tcp.2026.34.e9}
}
EUVIMED